ThursdayJan 26, 2023 1:45 pm

BioMedNewsBreaks – MetAlert Inc.’s (MLRT) Acquisition Target’s SafetyNet(R) Featured in New Article

MetAlert (OTC: MLRT), a leading solution provider for consumers/patients afflicted with movement, cognitive and spatial awareness disorders, recently announced that it offered $4.5 million in a cash and stock deal to acquire TrakTec LLC. Offering affordable, scalable location-awareness technology solutions, TrakTec made the news in a new Fairmont Post article that discusses its SafetyNet(R) service and others like it that are providing peace of mind for caregivers and loved ones and helping to quickly locate individuals who may be in danger. “Many police departments in the country have already begun to take advantage of these technologies to locate and rescue…

Continue Reading

ThursdayJan 26, 2023 11:54 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Virtual R&D Day

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has scheduled a virtual R&D Day for Feb. 28, 2023; the event is scheduled from 10 to 11:30 a.m. ET. The Cybin leadership team is slated to host the event, which will include an update on the company’s development pipeline of differentiated psychedelic-based therapeutics, including CYB003, which is being evaluated for the treatment of major depressive disorder, and CYB004, which is being evaluated for the treatment of generalized anxiety disorder. According to the announcement, the event will feature an interim readout from CYBN’s ongoing phase 1/2a…

Continue Reading

WednesdayJan 25, 2023 12:54 pm

BioMedNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Advances Novel Drug Candidate in Treating Alzheimer’s Symptoms

India Globalization Capital (NYSE American: IGC), in a historic first, has begun phase 2 clinical trials evaluating its flagship drug candidate, IGC-AD1, for the treatment of agitation in dementia from Alzheimer’s disease. “Company officials noted that, to their knowledge, this is the first natural low-dose THC-based compound to enter human trials for the treatment of symptoms such as agitation in dementia from Alzheimer’s disease. Currently there is no FDA-approved medication to treat agitation in Alzheimer’s,” reads a recent article. The piece quotes IGC CEO Ram Mukunda, who states, “We believe IGC-AD1 has the potential to revolutionize the treatment of the…

Continue Reading

WednesdayJan 25, 2023 11:38 am

BioMedNewsBreaks – MetAlert Inc. (MLRT) Announces Launch of Its Next-Gen SmartSole in Sweden

MetAlert (OTC: MLRT) today announced the launch of its new 4G GPS SmartSole in Sweden through its distribution partner Posifon AB. The upgraded GPS SmartSole introduction will be an important part of the national service agreement Posifon recently secured with major municipalities across Sweden related to providing home care, personal tracking and security for seniors. Initial shipments of the GPS SmartSole will be distributed to health care organizations, from memory care clinics to hospitals and social care organizations throughout Sweden. “We are excited to launch this next generation 4G Cat M1 GPS SmartSole in one of Europe’s most advanced health…

Continue Reading

WednesdayJan 25, 2023 10:26 am

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) $4.1M Placements Supported by Aegis Capital Corp. as Exclusive Placement Agent

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, recently announced the closing of both a registered direct and a private placement; the placements totaled approximately $4.1 million. Aegis Capital Corp. acted as exclusive placement agent for those placements. In the wealth management and investment banking business since 1984, Aegis has built a reputation for offering corporate finance and strategic advisory services to public and private companies across multiple sectors and regions. In addition, the company offers expert research and sales and trading services to institutional investors. Aegis provides a conflict-free service platform as well as…

Continue Reading

TuesdayJan 24, 2023 11:57 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses ‘Lifeblood’ of Phase 2 Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers in the brain and central nervous system, is enrolling patients in a phase 2 trial to evaluate the efficacy of its flagship drug candidate. The potentially pivotal trial will evaluate Berubicin for the treatment of glioblastoma multiforme (“GBM”), an aggressive brain tumor with an average overall survival rate of only 10-12 months. The company’s Chief Executive Officer John Climaco recently participated in the Virtual Investor “Ask the CEO” Event and discussed that enrollment in the trial was approaching 70 patients against a…

Continue Reading

TuesdayJan 24, 2023 11:32 am

BioMedNewsBreaks – MetAlert Inc. (MLRT) Approaching Inflection Point of Its Growth Curve

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring, is launching a suite of wearable companion products to its innovative SmartSole shoe insole units. “The patented GPS-enabled SmartSole is a non-intrusive tracking device designed to monitor the location of people with cognitive memory disorders such as Alzheimer’s Disease who tend to get lost or wander. The tech-designed insole may also be used by people at risk of kidnapping, such as children, government employees and select professionals. A next-generation shoe insole branded SmartSole plus incorporates biometric sensors paired with smart analytics to…

Continue Reading

TuesdayJan 24, 2023 10:55 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Names Senior Medical Tech Veteran as New President

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, has appointed Robert Eno to the newly created position of president. A senior medical technology executive, Eno will work to enhance the company’s strategic and operations capabilities. Eno brings a background of almost three decades experience in developing markets and commercializing disruptive medical technologies to his new role, where he will be essential in the company’s strategic direction, commercialization efforts, and day-to-day operations. Eno noted that he believes HeartBeam’s technology will be able to make a…

Continue Reading

TuesdayJan 24, 2023 10:05 am

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Closes on $4.1M Direct, Private Placement Offerings

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair, skin and sexual wellness, has closed on its previously announced registered direct offering and concurrent private placement. The offering includes the purchase and sale of 4,315,787 shares in a registered direct offering, with the concurrent private placement calling for JUPW to issue and sell a total of 8,631,574 warrants to the same investors. The warrants are to purchase up to one share of common stock each at an exercise price of $1 per share. According to the announcement, the private placement warrants will be exercisable six months after issuance. The…

Continue Reading

MondayJan 23, 2023 1:08 pm

BioMedNewsBreaks – Jupiter Wellness Inc.’s (NASDAQ: JUPW) Redeemable Digital Coupons Now Available for Shareholders of Record

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, today announced availability of its redeemable digital coupons for shareholders of record to claim on Upstream’s trading app. Upon successful claim, shareholders may redeem the digital coupon for a gift package of company products valued at over $179 or trade with others globally on Upstream to bring new potential customers into the community. The announcement reads, “By incorporating Upstream’s Web3 digital coupons into our strategy, we aim to provide our shareholders with first-hand experience of our products and bring new potential customers into our community to drive…

Continue Reading

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050